NCT01028053View on ClinicalTrials.gov

Assess the Prognostic Usefulness of Flutemetamol (18F) Injection for Identifying Subjects With Amnestic Mild Cognitive Impairment Who Will Convert to Clinically Probable Alzheimer's Disease

PHASE3CompletedINTERVENTIONAL
Enrollment

365

Participants

Timeline

Start Date

December 31, 2009

Primary Completion Date

January 31, 2014

Study Completion Date

January 31, 2014

Conditions
Mild Cognitive ImpairmentAlzheimer's Disease
Interventions
DRUG

Flutemetamol (18F) Injection

All subjects will receive an i.v. dose of (18F) flutemetamol (less than 10 mg flutemetamol). The nominal activity of a single administration of (18F) flutemetamol will be 185 MBq.

Trial Locations (1)

08540

GE Healthcare, Princeton

Sponsors

Lead Sponsor

GE Healthcare

Collaborators (1)

Medpace, Inc.
All Listed Sponsors
collaborator

Medpace, Inc.

INDUSTRY

collaborator

i3 Statprobe

INDUSTRY

collaborator

i3 Research

INDUSTRY

collaborator

Quintiles, Inc.

INDUSTRY

lead

GE Healthcare

INDUSTRY